ROL' POLOVYKh GORMONOV: ANDROGENOV I ESTROGENOV, V PROFILAKTIKE I TERAPII OSTEOPOROZA U MUZhChIN I ZhENShchIN


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article analyzes the role of estrogens and androgens in bone metabolism in men and women, as well as the importance of correction their deficits in the treatment of osteoporosis. The data of a randomized trial that compared the effects of monotherapy with estrogens and estrogen-androgen therapy in patients with osteoporosis are presented. The first group of patients received implants containing 50 mg of estrogen, a second group - implants containing 50 mg of estrogen and 100 mg of testosterone. After 3 years of treatment, there were no changes in bone mineral density (BMD) in first group, while metacarpal bone mineral density increased by 2 % in the second group. According to these findings, it was concluded that the use of androgens for the treatment of osteoporosis in women may be a promising direction and a field for further research on this issue.

Texto integral

Acesso é fechado

Bibliografia

  1. Clinicians guide to prevention and treatment of osteoporosis. NOF, 2013.
  2. Bertelloni S, Baroncelli GI, Federico G, et al. Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 1998;50(6):309-14.
  3. Ferlin A, Schipilliti M, Di Mambro A, et al. Osteoporosis in Klinefelter's syndrome. Mol Hum Reprod 2001,16(6):402-10.
  4. Issa C, Zantout MS, Azar TS. Osteoporosis in Men with Diabetes Mellitus. J Osteoporos 2011;651867.
  5. Rubin K. Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics 1998;8(102):481-85.
  6. Park C, Overton C. Premature menopause linked to CVD and osteoporosis. Practitioner 2010(3);254:21 -25.
  7. Mehler PS, Cleary BS, Gaudiani JL. Osteoporosis in anorexia nervosa. Eat Disord 2011;3(2): 194-202.
  8. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;4(28): 97-108.
  9. Gooren LJ, Toorians AW. Significance of oes-trogens in male (patho)physiology. Annales d'Endocrinologie 2003;64:126-35.
  10. Vermeulen A, Kaufman JM, Goemaere S & van Pottelberg I. Estradiol in elderly men. Aging Male 2002;5:98-102.
  11. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-74.
  12. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87:589-98.
  13. Simpso ER, Rubin G, Clyne C, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 2000;11:184-88.
  14. Labrie F, Belanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82:2403-09.
  15. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, et al. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 1998;49:803-09.
  16. Stepan JJ, Lachman M, Zverina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69:523-27.
  17. Rochira V, Faustini-Fustini M, Balestrieri A, Carani C. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters. J Clin Endocrinol Metab 2000;85:1841-45.
  18. Rochira V, Balestrieri A, Madeo B, Spaggiari A, Carani C. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol Cell Endocrinol 2002; 193:19-28.
  19. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endoc Rev 2004; 25:389-425.
  20. Benito M, Gomberg B, Wehrli RH, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003;88:1497-1502.
  21. Orwoll ES, Klein RF. Osteoporosis in men. Endoc Rev 1995;16:87-116.
  22. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
  23. Snyde PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-77.
  24. Crawford BAL, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003;88:3167-76. невозможно без коррекции гипогона-дизма. Применение андрогенов женщинами с целью лечения остеопороза на данный момент хоть не имеет убедительной доказательной базы, однако может являться перспективным направлением и полем для дальнейших научных исследований в данной области.
  25. Compston J. Local biosynthesis of sex steroids in bone. J Clin Endocrinol Metab 2002;87:5398-5400.
  26. Tollin SR, Rosen HN, Zurowski K, et al. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - a Clinical Research Center study. J Clin Endocrinol Metab 1996;81:1031-34.
  27. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:503-10.
  28. Ruetsche AG, Kneubueh lR, Birkhauser MH, Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term crosssex hormonal treatment: a cross-sectional study. Osteoporos Int 2005; 16:791 -98.
  29. Duan Y, Beck TJ, Wang XF, Seeman E. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. Journal of Bone and Mineral Research 2003;18:1766-74.
  30. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med 2003;349:327-34.
  31. Dagogo-JackS, al-AliN, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 1997;82:2821-25.
  32. Adami S, Zamberlan N, Castello R, et al. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol 1998; 48:169-73.
  33. Kasperk C, Fitzsimmons R, Strong D, et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab. 1990;71:1322-29.
  34. Haffner SM, Valdez RA. Endogenous sex hormones; Impact on lipids, lipoprotein and steroid levels in postmenopausal women. Acta Endocrinol 1986;11:419-23.
  35. Savvas M, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in postmenopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992;99(9):757-60.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies